Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

Single-center, open-label, two-stage pilot study examining the efficacy and safety of sparsentan for reducing high-grade proteinuria among patients with cancer who receive vascular endothelial growth factor inhibitors

NCT Number	NCT07224776
Lead Sponsor	Brigham and Women's Hospital Collaborators: Travere Therapeutics, Inc.
Conditions	Proteinuric Renal Disease, Proteinuric Kidney Disease, Proteinuria, Proteinuria in Nephrotic Range
Enrollment	20 participants
Start Date	2026-07-10
Primary Completion	2026-12-01 (estimated)
Study Completion	2028-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-30